'Mm clinical trial characteristics' diaporamas de présentation

Multiple Myeloma market landscape has undergone significant change over the past two decades. Forecast 2021.

Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. It is the second-most frequently diagnosed hematological malignancy, with an annual prevalence in the US of about 45,000. The disease is considered incurable, although the past decade has seen significant improvements in therapy, driven by a greater understanding of pathophysiology.

236 views • 5 slides